The early bactericidal activity of anti-tuberculosis drugs: a literature review

Tuberculosis

Volumn 88, Issue SUPPL. 1, 2008, Pages

  Donald, P R ^a,b   Diacon, A H ^a,b  

^a Faculty of Health Sciences   (Turkey)

^b DST/NRF Centre of Excellence for Biomedical TB Research

Author keywords

activity; Anti tuberculosis; Drug assessment; drugs; Early bactericidal; EBA; Tuberculosis

Indexed keywords

ACYLTRANSFERASE; AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PAROMOMYCIN; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN DERIVATIVE; RIFAPENTINE; STREPTOMYCIN; TIOCARLIDE; TUBERCULOSTATIC AGENT;

ACETYLATOR PHENOTYPE; ACID FAST BACTERIUM; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COLONY FORMING UNIT; DRUG BLOOD LEVEL; DRUG EFFICACY; EARLY BACTERICIDAL ACTIVITY; HUMAN; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPUTUM; SPUTUM CULTURE; SPUTUM CYTODIAGNOSIS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; DRUG MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, PULMONARY;

EID: 50649089808     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70038-6     Document Type: Article

References (49)

1. Fenner F., Martin S.P., and Pierce C.H. The enumeration of viable tubercle bacilli in cultures and infected tissues?. Ann NY Acad Sci 52 (1949) 751-764
2. Mitchison D.A. Development of streptomycin resistant strains of tubercle bacilli in pulmonary tuberculosis?. Thorax 5 (1950) 144-161
3. Joiner C.L., MacLean K.S., Chalmers D.G., et al. Chemotherapy of pulmonary tuberculosis?. Lancet 2 (1953) 152-158
4. Jensen K.A., Klaer I., Tørning K., and Haarhøj J. Chemotherapy in Tuberculosis?. Acta Tub Scand 29 (1954) 95-105
5. Crofton J., Brouet G., Daddi G., et al. Clinical methods of the evaluation of new antituberculosis drugs?. Bull Internat Union Tuberc 28 (1958) 247-289
6. Crofton J., and Stewart S.M. The choice of newer antituber-culosis drugs?. Bull Internat Union Tuberc 29 (1959) 600-611
7. Wissenschaftliche Arbeitsgemeinschaft für die Therapie von Lungenkrankheiten (W.A.T.L.). Kooperatiewe, kontrollierte Prüfung von Thiocarlide (DATC), PAS und Bettruhe in kurzfristiger Monotherapie bie kavernöser vorbehandelter Lungentuberkulose?. Beitr Klin Tuberk 139 (1969) 115-139
8. Schütz I. A comparison of rifampicin, ethambutol and PAS in short-term monotherapy. Preliminary results of the third cooperative study of WATL?. Acta Tuberc Pneumol Belg 60 (1969) 437-441
9. Hobby G.L., Holman A.P., Iseman M.D., and Jones J.M. Enumeration of tubercle bacilli in sputum of patients with pulmonary tuberculosis?. Antimicrob Agents Chemother 4 (1973) 94-104
10. Jindani A., Aber V.R., Edwards E.A., and Mitchison D.A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis?. Am Rev Respir Dis 121 (1980) 939-949
11. Jindani A., Doré C., and Mitchison D.A. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days?. Am J Respir Crit Care Med 167 (2003) 1348-1354
12. Mitchison D.A., and Sturm A.W. The measurement of early bactericidal activity?. Balliéres Clin Infect Dis 4 (1997) 185-206
13. Chan S.L., Yew W.W., Ma W.K., et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis?. Tubercle Lung Dis 73 (1992) 33-38
14. Kennedy N., Fox R., Kisyombe G.M., et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis?. Am Rev Respir Dis 148 (1993) 1547-1551
15. Sirgel F.A., Botha F.J.H., Parkin D.P., et al. The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment?. J Antimicrob Chemother 32 (1993) 867-875
16. Donald P.R., Sirgel F.A., Botha F.J., et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis?. Am J Respir Crit Care Med 156 (1997) 895-900
17. Sirgel F.A., Botha F.J., Parkin D.P., et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis?. Am J Respir Crit Care Med 156 (1997) 901-905
18. Hafner R., Cohn J.A., Wright D.J., et al. Early bactericidal activity of isoniazid in pulmonary tuberculosis. Optimization of methodology?. Am J Respir Crit Care Med 156 (1997) 918-923
19. Chambers H.F., Kogacöz T., Sipit T., Turner J., and Hopewell P.C. Activity of amoxicillin/clavulanate in patients with tuberculosis?. Clin Infect Dis 26 (1998) 874-877
20. Sirgel F.A., Donald P.R., Odhiambo J., et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs?. J Antimicrob Chemother 45 (2000) 859-870
21. Dietze R., Teixeira L., Márcia L., et al. Safety and bactericidal activity of rifalazil in patients with pulmonary The early bactericidal activity of anti-tuberculosis drugs: a literature review S83 tuberculosis?. Antimicrob Agents Chemother 45 (2001) 1972-1976
22. Gosling R.D., Uiso L.O., Sam N.E., et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuber-culosis?. Am J Respir Crit Care Med 168 (2003) 1342-1345
23. Pletz M.W.R., and De R. A, Roth A, Neuman K-H, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective randomized study?. Antimicrob Agents Chemother 48 (2004) 780-782
24. Donald P.R., Sirgel F.A., Venter A., et al. The influence of human N-acetyltransferase genotype on the early bacteri-cidal activity of isoniazid?. Clin Infect Dis 39 (2004) 1425-1430
25. Johnson J.L., Hadad D.J., Boom W.H., et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis?. Int J Tuberc Lung Dis 10 (2006) 605-612
26. Sirgel F.A., Fourie P.B., Donald P.R., et al. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis?. Am J Respir Crit Care Med 172 (2005) 128-135
27. Diacon A.H., Patentia R.F., Venter A., et al. The early bactericidal activity of high dose rifampin in patients with sputum smear-positive pulmonary tuberculosis?. Antimicrob Agents Chemother 51 (2007) 2994-2996
28. Hirata T., Saito H., Tomioka H., et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis?. Antimicrob Agents Chemother 39 (1995) 2295-2303
29. Gillespie S.H., Gosling R.D., Uiso L., Sam N.E., Kanduma E.G., and McHugh T.D. Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis?. J Antimicrob Chemother 56 (2005) 1169-1171
30. Donald P.R., Sirgel F.A., Venter A., et al. The early bactericidal activity of streptomycin?. Int J Tuberc Lung Dis 6 (2002) 693-698
31. Donald P.R., Sirgel F.A., Venter A., et al. The early bactericidal activity of amikacin in pulmonary tuberculosis?. Int J Tuberc lung Dis 5 (2001) 533-538
32. Donald P.R., Sirgel F.A., Kanyok T.P., et al. Early bactericidal activity of paromomycin (aminosidine) in patients with smear-positive pulmonary tuberculosis?. Antimicrob Agents Chemother 44 (2000) 3285-3287
33. Donald P.R., Sirgel F.A., Venter A., et al. The early bactericidal activity of low-clearance liposomal amikacin in pulmonary tuberculosis?. J Antimicrob Chemother 48 (2001) 877-880
34. Tokuoka S., Oka S., Narusawa T., and Kondo J. A study of the effectiveness of aminosidine against pulmonary tuberculosis?. Japn J Chest Dis 29 (1970) 550-553
35. Dickinson J.M., Aber V.R., and Mitchison D.A. Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol and pyrazinamide alone and in combination against Mycobacterium tuberculosis?. Am Rev Respir Dis 116 (1977) 627-635
36. Botha F.J.H., Sirgel F.A., Parkin D.P., and van d. Wal BW, Donald PR, Mitchison DA. Early bactericidal activity of ethambutol, pyrazinamide and the fixed dose combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis?. S Afr Med J 86 (1996) 155-158
37. Donald P.R., Sirgel F.A., Venter A., et al. Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis?. Scand J Infect Dis 33 (2001) 466-469
38. Donald P.R., Parkin D.P., Seifart H.I., et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmaco-dynamics of isoniazid?. Eur J Clin Pharmacol 63 (2007) 633-639
39. Sirgel F., Venter A., and Mitchison D. Sources of variation in studies of the early bactericidal activity of antituber-culosis drugs?. J Antimicrob Chemother 47 (2001) 177-182
40. Gillespie S.H., and Kennedy N. Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis?. J Antimicrob Chemother 34 (1994) 181-183
41. Sirgel F.A., Botha F.J.H., Parkin D.P., and van d. Wal BW, Donald PR, Mitchison DA. Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis?. J Antimicrob Chemother 34 (1994) 181-183
42. Gillespie S.H., Gosling R.D., and Charalambous B.M. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs?. Am J Respir Crit Care Med 166 (2002) 31-35
43. Gosling R.D., Heifets L., and Gillespie S.H. A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs?. J Antimicrob Chemother 52 (2003) 473-476
44. Donald P.R., Sirgel F.A., Venter A., et al. Early bactericidal activity of antituberculosis agents?. Expert Rev Anti-infect Ther 1 (2003) 141-155
45. Epstein M.D., Schluger N.W., Davidow A.L., Bonk S., Rom W.N., and Hanna B. Time to detection of Mycobacterium tuber-culosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis?. Chest 113 (1998) 379-386
46. Kennedy N., Gillespie S.H., Saruni A., et al. Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis?. J Infect Dis 170 (1994) 713-716
47. Yajko D.M., Wagner C., Tevere V.J., Kogacöz T., Hadley W.K., and Chambers H.F. Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by Amplicor PCR assay?. J Clin Microbiol 33 (1995) 1944-1947
48. Wallis R.S., Perkins M., Phillips M., et al. Induction of antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment?. J Infect Dis 178 (1998) 1115-1121
49. Desjardin L.E., Perkins M.D., Wolski K., et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy?. Am Rev Respir Dis 160 (1999) 203-210